Encapsulated Islet Cell Transplants Avoid Host Immune Rejection

A technology that has been under development for several years -- encapsulating islets cells with polyethylene glycol -- may soon obviate the need for immunosuppression in islet cell transplantation, according to a presentation at the American Diabetes Association's 65th Annual Scientific Sessions in San Diego, California. The net result will be effective control of blood glucose levels in patients with insulin-dependent diabetes without the danger of hypoglycemia or graft rejection, lead presenter Dr. David Scharp told Reuters Health. Dr. Scharp is chief scientific officer and executive vice president of research and development at Novocell, Inc. in Irvine California.
Taken from ADA online Diabetes E-News now